NUZ.ASX: NUZ-001 Shows Positive Results in Human 3D Brain Model

NUZ-001 Shows Positive Results in Human 3D Brain Model

Stock	NUZ.ASX (NUZ.ASX)
Release Time	1 Apr 2025, 9:03 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

NUZ-001 Shows Positive Results in Human 3D Brain Model

Key Points

Completion of independent study with Tessara Therapeutics to assess the effect of NUZ-001
Results showed NUZ-001 and NUZ-001 Sulfone exhibited strong safety characteristics and suggested short-term treatment promotes health, neuroprotection, and neuroplasticity
Additional study underway to explore the therapeutic potential of NUZ-001 in Tessara's ADBrain model for sporadic Alzheimer's disease

Full Summary

Neurizon Therapeutics Limited (ASX: NUZ) announced that results from an independent study undertaken in collaboration with Tessara Therapeutics will be presented at the AD/PD 2025 Advances in Sciences & Therapy conference. The study assessed the effect of Neurizon's lead candidate, NUZ-001, in Tessara's RealBrain® 3D human micro-tissues model. The results showed that NUZ-001 and NUZ-001 Sulfone (major active metabolite) exhibited an excellent safety profile in the ArtiBrain™ model (healthy human brain) and suggested short-term treatment: promotes health and viability of brain tissues, has neuroprotective properties against neurotoxic insult, and may promote neuroplasticity by boosting neuronal branching. These findings indicate that short-term treatment with NUZ-001 and NUZ-001 Sulfone maintains an excellent safety profile and offers neuroprotective effects against ferroptosis, a unique form of programmed cell death, as well as encouraging neural branching, potentially boosting plasticity. Further research is needed to clarify the mechanisms, but the current data suggest longer-term treatment may enhance network density and overall plasticity, which could translate into benefits in cognition, learning, memory, or resilience to neurodegenerative processes. As part of ongoing initiatives with Tessara, the therapeutic efficacy of NUZ-001 is now being assessed through Tessara's ADBrain™ platform for sporadic Alzheimer's disease, with results expected this quarter.

Outlook

Further research is needed to clarify the mechanisms responsible for the neuroprotective and neuroplasticity benefits observed with NUZ-001 and NUZ-001 Sulfone in the 3D human brain model. Additional study results are expected this quarter to assess the therapeutic potential of NUZ-001 in Tessara's ADBrain™ model for sporadic Alzheimer's disease.